---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021674"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:39:56.336275+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M

## Summary
- Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).
- Net loss $53.5M ($0.55 loss per ADS) vs $49.1M in Q1 2023; R&D $54.6M, SG&A $69.2M.
- Cash $750.8M at Mar 31, 2024, down from $806.5M at Dec 31, 2023.
- Appointed Andrew Zhu as Chief Commercial Officer for Greater China in April 2024.
- Regulatory milestones: sBLA submitted for efgartigimod SC in CIDP; potential NMPA approvals for repotrectinib, sulbactam-durlobactam, efgartigimod SC in gMG in 2024.

## SEC filing metadata
- accession: 0001628280-24-021674
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/0001628280-24-021674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/zlab-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021674
- JSON: https://secwatch.observer/filing/0001628280-24-021674.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021674.txt

## Key facts
- Earnings Releases
  Zai Lab Ltd reported the first quarter of 2024 results: revenue $87.1 million, net income $53.5 million, EPS loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55).
  - Period: the first quarter of 2024
  - Revenue: $87.1 million
  - Net income: $53.5 million
  - EPS: loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55)
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) sales of $13.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/0001628280-24-021674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.